Tatva Chintan Pharma (TATVA) | Stock Overview & Key Data
Tatva Chintan Pharma Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹2,977.80 on November 1, 2021
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Dividend Information
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Tatva Chintan Pharma
TATVA
|
29.71B Small-cap | 5.11% | -8.88% | 7.24% | -16.21% | -10.09% | 25.48% | -31.35% | -50.03% | -50.03% | -50.03% | -50.03% |
|
Asian Paints
ASIANPAINT
|
2.38T Large-cap | -0.39% | 8.72% | 16.47% | -10.00% | -3.28% | 18.26% | -17.47% | -8.66% | 160.57% | 743.36% | 4,411.31% |
|
Pidilite Industries
PIDILITIND
|
1.43T Large-cap | -0.79% | 7.80% | 2.22% | -0.92% | 0.12% | -4.25% | 13.02% | 43.08% | 319.01% | 1,801.03% | 6,075.76% |
|
Tanfac Industries
TANFACIND
|
49.61B Small-cap | -2.58% | -18.82% | -1.31% | -0.16% | -7.86% | 29.08% | 107.16% | 1,664.40% | 11,884.41% | 13,950.69% | 11,143.65% |
|
Gulf Oil Lubricants
GULFOILLUB
|
48.12B Small-cap | -2.53% | -7.31% | -13.33% | -22.39% | -25.44% | -17.97% | 112.46% | 39.16% | 79.61% | 269.35% | 269.35% |
|
Neogen Chemicals
NEOGEN
|
44.76B Small-cap | 1.33% | 11.63% | 38.07% | 75.61% | 60.11% | 10.59% | 19.04% | 106.75% | 609.06% | 609.06% | 609.06% |
Ownership & Short Interest
Calculate Your Tatva Chintan Pharma Investment Returns
Long-Term Investment Performance Analysis
Tatva Chintan Pharma stock price in Jul 2021 was ₹2,267.85, A ₹1,000.00 lump sum investment in Tatva Chintan Pharma made 4 years ago would be worth approximately ₹521.86 today, representing a negative return of -47.81%. This translates to an annualized return (CAGR) of -12.53%.
4 Years 10 Months Investment Scenario (Jul 2021 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is TATVA's 52-week high and low?
- In the last 52 weeks, Tatva Chintan Pharma reached a high of ₹1,610.00 (on November 18, 2025) and a low of ₹886.00 (on June 20, 2025).
- What is the market cap and P/E ratio for TATVA?
- Curious about Tatva Chintan Pharma's size and valuation? Its market capitalization stands at 29.71B. When it comes to valuation, the P/E ratio (trailing twelve months) is 93.92, and the forward P/E (looking ahead) is 45.99.
- Does TATVA pay dividends? If so, what's the yield?
- Yes, Tatva Chintan Pharma is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.10%, and the company has paid an average of ₹1.67 per share annually over the past 3 years.
- Who are Tatva Chintan Pharma's main competitors or similar companies to consider before investing?
When looking at Tatva Chintan Pharma, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Asian Paints
ASIANPAINT2.38T Basic Materials Specialty Chemicals 18.26% -17.47% Pidilite Industries
PIDILITIND1.43T Basic Materials Specialty Chemicals -4.25% 13.02% Tanfac Industries
TANFACIND49.61B Basic Materials Specialty Chemicals 29.08% 107.16% Gulf Oil Lubricants
GULFOILLUB48.12B Basic Materials Specialty Chemicals -17.97% 112.46% Neogen Chemicals
NEOGEN44.76B Basic Materials Specialty Chemicals 10.59% 19.04% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Tatva Chintan Pharma Chem Limited? (e.g., ROE, Debt/Equity)
- To get a sense of Tatva Chintan Pharma's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 0.77%, the Debt to Equity ratio from the most recent quarter is 11.00, and its Gross Profit Margin stands at 58.01%.
- What is the recent revenue and earnings growth for TATVA?
- Looking at Tatva Chintan Pharma's growth, its revenue over the trailing twelve months (TTM) was INR5B. Compared to the same quarter last year (YoY), quarterly revenue grew by 52.90%, and quarterly earnings saw a YoY growth of 10,889.10%.
- How much of TATVA stock is held by insiders and institutions?
- Wondering who owns Tatva Chintan Pharma stock? Company insiders (like executives and directors) hold about 74.16% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 5.31%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.